BCDI is committed to providing the most cutting edge treatment opportunities for bleeding disorder patients. To achieve this commitment, BCDI participates in a variety of clinical trials for bleeding disorder patients.

What is a clinical trial?  Click here to download more information about clinical trials.

What is informed consent?   Click here to download more information about informed consent.

Clinical Trials

The following clinical trials are currently available at BCDI. Click on the links below to learn more information.

Hemophilia A and B

Pediatric Patients

•Baxalta 261203 - Phase 3 prospective study of the safety and efficacy of Prophylactic BAX855 in previously un-treated patients with severe hemophilia A  <6 years old

https://clinicaltrials.gov/ct2/show/NCT02615691

von Willebrand Disease

• Zimmerman/RO1- This study is to improve the investigators ability to diagnose von Willebrand Disease (VWD), a common inherited bleeding disorder. This study will look at a new screening blood test used to determine if a person has VWD.

https://clinicaltrials.gov/ct2/show/NCT02466789

• Shire 071102 - A study of recombinant von Willebrand factor with or without Advate to treat and control bleeding episodes, elective and emergency surgeries in children diagnosed with severe von Willebrand disease. 
https://clinicaltrials.gov/ct2/show/NCT02932618

Venous Thrombosis 

• Pfizer B0661037 - Study Of Apixaban Versus Standard Of Care In Pediatric Patients Requiring Anticoagulation For The Treatment Of A Venous Thromboembolic Event

http://clinicaltrials.gov/ct2/show/study/NCT02464969

Immune Thrombocytopenia Purpura (ITP)

Adult Patients

• PRN1008-010: Adaptive, open-label, dose-finding, phase 1/2 study investigating the safety, pharmacokinetics and clinical activity of PRN1008, an oral BTK inhibitor, in patients with relapsed immune thrombocytopenic purpura.

https://clinicaltrials.gov/ct2/show/NCT03395210

• TAK-079: Study to evaluate safety, tolerability, and efficacy of TAK-079 in participants with persistent/chronic Primary Immune thrombocytopenia. 

http://clinicaltrials.gov/ct2/show/NCT04278924

Pediatric Patients

• AVA-PED-301:  Randomized double-blind, placebo controlled, Open-label study to evaluate the efficacy and safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric subjects with Immune Thrombocytopenia.

https://clinicaltrials.gov/ct2/show/NCT04516967?recrs=a&cond=ITP&cntry=US&draw=2&rank=10 

Data Collection Studies

Data Collection Studies gather clinical data on bleeding disorder patients and the data helps physicians develop best practices for the treatment of bleeding disorder patients.

The following Data Collection Studies are currently being done at BCDI. Click the links below to learn more information. 

Hemophilia

HUGS VIII - Costs and impact of disease in people with Hemophilia A.

von Willebrand Disease

ATHN 9 - VWD Natural History Study: Safety and effectiveness of the treatments used for people with von Willebrand Disease.

General Bleeding/Clotting Disorders

•ATHNDATA SET: ATHN's safe and secure national patient health data resource - the ATHNdataset - has grown to include over 23,646 patients who have chosen to "opt-in" by signing a patient authorization at their Hemophilia Treatment Center (HTC).

http://athn.org

 •CDC REGISTRY- CDC Public Health Surveillance for bleeding Disorders - Registry for bleeding disorders surveillance.

http://athn.org/?q=content/public-health-surveillance

 •SCNIR: Severe Chronic neutropenia International Registry an organization dedicated to improving understanding and treatment for diseases causing severe chronic neutropenia. 

http://depts.washington.edu/registry

•Outcomes of Regional Consensus Treatment Guidelines for Management of Surgery, Invasive Procedures and Control of Hemorrhages in Patients with Bleeding Disorders; and Management of Thrombosis and Thromboprophylaxis in patients with Thrombophilia.